Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY3405105 in advanced solid tumors
NCT03770494Phase 1Terminated
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2019
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 1, open-label trial of LY3405105 in solid tumor (2 arms), sponsored by Eli Lilly and Company. Primary endpoints: Dose Limiting Toxicities at 28 days and Objective Response Rate at 6 months. Started Jan 2019; status: terminated.
02
Drugs
LY3405105
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03770494.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03770494.